Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab RCT for AI-associated bone loss in postmenopausal breast cancer
jRCTs051180211Completed
- Sponsor
- Japanese Breast Cancer Society
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of denosumab in breast cancer, osteopenia and osteoporosis (2 arms), sponsored by Japanese Breast Cancer Society. Primary endpoint: Lumbar spine BMD change at 12 months. Started Sep 2017; status: completed.
02
Drugs
denosumab
03
Conditions
breast cancerosteopeniaosteoporosis
Beyond the preview
Go deeper on jRCTs051180211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180211.